Article Text

This article has a correction. Please see:

PDF
Are anti-cyclic citrullinated peptide autoantibodies seromarkers for rheumatoid vasculitis in a cohort of patients with systemic vasculitis?
  1. K Laskaria1,
  2. K Ahmadi-Simab1,2,
  3. M Lamken1,
  4. E Csernok1,
  5. W L Gross1,
  6. B Hellmich1,3
  1. 1
    Department of Rheumatology, University Hospital of Schleswig-Holstein, Campus Lübeck and Rheumaklinik Bad Bramstedt, Lübeck, Germany
  2. 2
    Regio Kliniken Wedel, Wedel, Germany
  3. 3
    Kreiskliniken Esslingen, Plochingen, Germany
  1. Correspondence to K Laskaria, Department of Rheumatology, University Hospital of Schleswig-Holstein, Campus Lübeck and Rheumaklinik Bad Bramstedt, Ratzeburger Allee 160, 23538 Lübeck, Germany; katerina_laskari{at}yahoo.gr

Statistics from Altmetric.com

A diverse spectrum of vasculitic syndromes exists including systemic rheumatoid vasculitis (SRV), which sometimes occurs as the first manifestation of severe rheumatoid factor (RF)-positive rheumatoid arthritis.1 So far, no convincing laboratory parameter has been determined for the diagnosis of SRV, which helps in distinguishing rheumatoid vasculitis from other types of small-sized or medium-sized vessel vasculitides. The aim of our study was to estimate the potential diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies among the systemic vasculitides.2

A total of 27 consecutive patients with SRV at vasculitis diagnosis were included in the study;3 27 patients with seropositive rheumatoid arthritis (RA) without vasculitis, matched for age, sex and disease duration with the SRV group, and 151 patients with primary systemic small vessel vasculitis (PSV) (50 patients with Wegener granulomatosis (WG), 50 patients with microscopic polyangiitis (MPA) …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd and European League Against Rheumatism